TY - JOUR
T1 - Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas
AU - Parker Kerrigan, Brittany C.
AU - Shimizu, Yuzaburo
AU - Andreeff, Michael
AU - Lang, Frederick F.
N1 - Funding Information:
This work was funded by grants from the National Cancer Institute grant P50 CA127001 (SPORE in Brain Cancer), the Broach Foundation for Brain Cancer Research, the Elias Family Fund, and the Priscilla and Jason Hiley Fund (all to FFL). We thank David M. Wildrick, Ph.D., for editorial support.
Publisher Copyright:
© 2017 International Society for Cellular Therapy
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.
AB - Mesenchymal stromal cells (MSCs) are a type of adult stem cell that has been exploited for the treatment of a variety of diseases, including cancer. In particular, MSCs have been studied extensively for their ability to treat glioblastoma (GBM), the most common and deadly form of brain cancer in adults. MSCs are attractive therapeutics because they can be obtained relatively easily from patients, are capable of being expanded numerically in vitro, can be easily engineered and are inherently capable of homing to tumors, making them ideal vehicles for delivering biological antitumoral agents. Oncolytic viruses are promising biological therapeutic agents that have been used in the treatment of GBMs, and MSCs are currently being explored as a means of delivering these viruses. Here we review the role of MSCs in the treatment of GBMs, focusing on the intersection of MSCs and oncolytic viruses.
KW - adenovirus
KW - gliomas
KW - mesenchymal stem cell
KW - mesenchymal stromal cell
UR - http://www.scopus.com/inward/record.url?scp=85013213769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013213769&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2017.02.002
DO - 10.1016/j.jcyt.2017.02.002
M3 - Review article
C2 - 28233640
AN - SCOPUS:85013213769
SN - 1465-3249
VL - 19
SP - 445
EP - 457
JO - Cytotherapy
JF - Cytotherapy
IS - 4
ER -